VALUE OF BONE BIOMARKERS IN POSTMENOPAUSAL WOMEN
Dr. Susana Adriana Vilarino
15 slide(s) – English – 2012-03-28
Osteoporosis is a polygenetic ,multifacetic, metabolic disorder necesity a complete understanding of its etiopathology..
Bone density often begins to decline prior to mild adulthood before woman’s estrogen levels begin to recede.
Biomarkers testing allows detection of metabolic change long before alterations in BMD.
Objective:The purpose of study was to evaluate the interest of different bone biomarkers in the diagnostic of osteoporosis in postmenopausal women.
Method: A transverse descriptive study enrrolled 71 patients , 14.osteopenic and 37osteoporotic women. The two groups were defined by bone density measurment.
The follows markers were measured Serum osteocalcin, crosslink N teopeptide, SHBG, PTH,Calcium and 25OH vitamine D were measured using inmunoassay.
We found and iinverse rellatiionshiip between lumbar BMD and
SHBG (T Score <-1 = 58,,66 \" T Score >-1 =45,,58 P= 0..041)
And a positive association with osteocalcin levels and lumbar BMD
(T Score <-2=17,22 \" T Score <-1 to -2= 23,12 \" T Score >-1
We have compared SHBG and OSTEOCALCIN.in osteopenic and osteoporotic postmenopausal patients
An increase in bone turn over markers levels is associated with an increase risk of hip and non vertebral fractures in elderly women over 75 years old.
The combination of data from bone mineral density and bone resorption markers may improve fracture prediction.
The positive asociation whith osteocalcin levels and the invers relation with SHBG was greater in the group of osteoporotic women and appeared therefore to be a good bone turnover marker in the diagnosis of osteoporosis and risk of hip and non vertebral fractures